Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering

Rhea-AI Summary

Anteris Technologies Global Corp (NASDAQ: AVR) priced a public offering of 34,782,609 shares at $5.75 per share, generating approximately $200.0 million in gross proceeds, with expected closing on January 22, 2026.

The company granted underwriters a 30-day option to buy an additional 5,217,391 shares. Separately, Anteris agreed to a private placement to Medtronic of up to $90.0 million of shares at the same price, subject to a minimum purchase equal to 16.0% and a maximum of 19.99% of post-offering outstanding shares; the private placement is contingent on the Offering.

Net proceeds are intended to fund the global pivotal PARADIGM Trial for the DurAVR THV, expand manufacturing, support R&D at v2vmedtech, and for working capital.

Positive

• Gross proceeds of $200.0M from the public offering
• Planned funding for the PARADIGM pivotal trial of DurAVR THV
• Up to $90.0M committed potential private investment from Medtronic

Negative

• Share dilution from issuance of 34,782,609 new shares and potential 5,217,391 overallotment
• Medtronic private placement could result in up to 19.99% ownership post-offering
• Offering is not contingent on Medtronic private placement, so planned Medtronic funding is not guaranteed

News Market Reaction

+12.52% 15.5x vol

49 alerts

+12.52% News Effect

+70.3% Peak in 7 hr 48 min

+$30M Valuation Impact

$273M Market Cap

15.5x Rel. Volume

On the day this news was published, AVR gained 12.52%, reflecting a significant positive market reaction. Argus tracked a peak move of +70.3% during that session. Our momentum scanner triggered 49 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $30M to the company's valuation, bringing the market cap to $273M at that time. Trading volume was exceptionally heavy at 15.5x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Public offering price: $5.75 per share Offering size: $200 million Shares offered: 34,782,609 shares +5 more

8 metrics

Public offering price $5.75 per share Pricing of 34,782,609 common shares in public offering

Offering size $200 million Gross proceeds from public offering before fees and expenses

Shares offered 34,782,609 shares Common stock sold by the company in the public offering

Underwriter option shares 5,217,391 shares 30-day option for additional shares at public offering price

Medtronic private placement Up to $90.0 million Private placement at public offering price, contingent on offering close

Minimum Medtronic stake 16.0% Minimum of post-offering common shares outstanding in private placement

Maximum Medtronic stake 19.99% Maximum of post-offering common shares outstanding in private placement

Today’s price move 12.52% Pre-news 24h price change associated with offering news flow

Market Reality Check

Price: $6.06 Vol: Volume 1,191,221 is 4.34x...

high vol

$6.06 Last Close

Volume Volume 1,191,221 is 4.34x the 20-day average of 274,761, indicating heavy pre-offering trading. high

Technical Shares traded above the 200-day MA, with price at $5.75 versus MA $4.24 before this pricing news.

Peers on Argus

AVR gained 12.52% while key peers showed modest, mixed moves (e.g., KRMD +1.64%,...

AVR gained 12.52% while key peers showed modest, mixed moves (e.g., KRMD +1.64%, MBOT +0.48%, NYXH -1.05%, INFU -2.44%, UTMD +0.48%), pointing to a stock-specific reaction.

Historical Context

5 past events · Latest: Jan 20 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 20	Equity offering & investment	Neutral	+12.5%	$200M offering and up to $90M Medtronic private placement announcement.
Nov 17	Clinical data update	Positive	-3.3%	30-day outcomes in 100 DurAVR THV patients with strong safety and efficacy.
Nov 12	Earnings and update	Negative	-2.6%	Q3 2025 cash burn, limited cash, and continued development-stage losses.
Nov 03	FDA trial approval	Positive	-3.1%	FDA IDE approval to initiate PARADIGM global pivotal trial for DurAVR THV.
Oct 28	Clinical outcomes data	Positive	-7.8%	One-year small-annulus DurAVR data with no valve-related mortality or severe leak.

Pattern Detected

Clinical and regulatory positives have often seen negative price reactions, while financing/strategic capital news has coincided with gains.

Recent Company History

Over recent months, Anteris has advanced its DurAVR® THV program with favorable hemodynamic data, including one-year results in 65 small‑annulus patients and 30‑day outcomes in 100 patients, yet those updates saw declines of -7.84% and -3.25%. FDA approval to initiate the PARADIGM global IDE trial on November 3, 2025 also coincided with a -3.12% move. In contrast, the January 2026 financing plus Medtronic strategic investment news linked to this offering tag saw a +12.52% reaction, highlighting stronger market appetite for de-risking capital events than for clinical milestones.

Market Pulse Summary

The stock surged +12.5% in the session following this news. A strong positive reaction aligns with t...

Analysis

The stock surged +12.5% in the session following this news. A strong positive reaction aligns with the market’s prior response to this capital-raise theme, where related news saw a +12.52% move. The pricing locks in $5.75 for 34,782,609 new shares and up to $200 million in gross proceeds, with an additional Medtronic commitment of up to $90.0 million. Investors may weigh balance-sheet de‑risking against dilution, especially given past negative reactions to clinical and regulatory milestones.

Key Terms

public offering, underwriters, private placement, shelf registration statement, +3 more

7 terms

public offering financial

"today announced the pricing of its public offering (the “Offering”) of 34,782,609 shares"

A public offering is when a company sells shares to the general public through the stock market, either by issuing new shares to raise cash or by letting existing owners sell their stakes. Think of it like a business opening its doors to many new owners at once: it can bring in money for growth but also increases the number of shares available, which can change the stock price and dilute existing ownership — key factors investors watch closely.

underwriters financial

"the Company has granted the underwriters a 30-day option to purchase up to an additional"

Underwriters are financial professionals or institutions that help companies raise money by selling new securities, such as stocks or bonds, to investors. They assess the risk and determine the price at which these securities should be sold, acting like a bridge between the company and the investors. Their role helps ensure that the company raises the needed funds while providing investors with options that reflect the level of risk involved.

private placement financial

"has agreed to sell to Medtronic plc ... in a private placement exempt from the registration"

A private placement is a way for companies to raise money by selling securities directly to a small group of investors instead of through a public offering. This process is often quicker and less regulated, making it similar to offering a special, exclusive investment opportunity to select individuals or institutions. For investors, it can provide access to unique investment options that are not available on public markets.

shelf registration statement regulatory

"The Shares are being offered by the Company pursuant to a shelf registration statement on Form S-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"pursuant to a shelf registration statement on Form S-3 (the “Form S-3 Registration Statement”)"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

prospectus supplement regulatory

"A preliminary prospectus supplement and accompanying prospectus relating to and describing"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

stabilizing actions financial

"the underwriters may engage in stabilizing actions or related activities in connection"

Stabilizing actions are deliberate steps taken by a company, its underwriters, or market participants to support a security’s price and reduce sharp swings after a trade, offering, or news event. Think of it as temporary hand-holds placed on a slippery slope: these measures (such as buying shares, coordinating orderly selling, or using option provisions) help maintain liquidity and investor confidence, which can limit short-term losses or disorderly market behavior that might otherwise misrepresent long-term value.

AI-generated analysis. Not financial advice.

MINNEAPOLIS and BRISBANE, Australia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the pricing of its public offering (the “Offering”) of 34,782,609 shares of its common stock (the “Shares”). The Shares are being sold at a public offering price of $5.75 per share. The gross proceeds to the Company from the Offering, prior to deducting underwriting discounts, commissions and estimated offering expenses, are expected to be approximately $200 million. The Offering is expected to close on January 22, 2026, subject to the satisfaction of customary closing conditions.

All Shares to be sold in the Offering are being sold by the Company. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 5,217,391 Shares from the Company at the public offering price, less underwriting discounts and commissions.

In addition, pursuant to a stock purchase agreement, dated January 20, 2026, Anteris has agreed to sell to Medtronic plc (through a wholly owned subsidiary) in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended, and at a price per share equal to the public offering price in the Offering, up to $90.0 million of shares of common stock, subject to a minimum purchase of 16.0% of the number of shares of common stock outstanding after the Offering and a maximum purchase of 19.99% of the number of shares of common stock outstanding after the Offering (the “Private Placement”). Completion of the Private Placement is contingent on completion of the Offering; however, the Offering is not contingent on the completion of the Private Placement.

Anteris intends to use the net proceeds from the Offering, together with its existing cash and cash equivalents and the net proceeds from the Private Placement, to support the next stage of growth and advance execution of the Company’s clinical strategy. This includes ongoing recruitment and study execution of the DurAVR^® Transcatheter Heart Valve (“DurAVR^® THV”) global pivotal trial for patients with severe aortic stenosis (the “PARADIGM Trial”) and expansion of manufacturing capabilities. In addition, a portion of the proceeds is expected to fund ongoing research and development for v2vmedtech, inc., with the balance allocated to working capital and other general corporate purposes determined from time to time.

Barclays, Wells Fargo Securities and Cantor are acting as joint book-running managers for the Offering. Barrenjoey Markets Pty Limited is acting as financial advisor in connection with the Offering to investors in Asia-Pacific and certain other jurisdictions outside of the United States and Canada. Wells Fargo Securities is acting as sole placement agent in connection with the private placement of Anteris’ shares to Medtronic.

The Shares are being offered by the Company pursuant to a shelf registration statement on Form S-3 (the “Form S-3 Registration Statement”) that was filed with the Securities and Exchange Commission (the “SEC”) and declared effective on January 8, 2026. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the Offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the Offering may be obtained from: Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (888) 603-5847 or by e-mail at barclaysprospectus@broadridge.com; Wells Fargo Securities, LLC, 90 South 7th Street, Minneapolis, MN 55402, by telephone at (800) 645-3751 (option #5), or by email at WFScustomerservice@wellsfargo.com; or Cantor Fitzgerald & Co., by mail at Attention: Capital Markets, 110 East 59th Street, New York, NY 10022, or by email at prospectus@cantor.com.

The shares of common stock offered and sold in the Private Placement have not been registered under the Securities Act or any state’s securities laws. Accordingly, such securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. The prospectus supplement and the accompanying prospectus related to the Offering are not an offer to sell or a solicitation of an offer to buy any securities in connection with the Private Placement.

This press release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities, and shall not constitute an offer, solicitation or sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. As disclosed in the preliminary prospectus supplement related to the Offering, the underwriters may engage in stabilizing actions or related activities in connection with the Offering.

About Anteris

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.

Anteris’ lead product, the DurAVR^® THV, was designed in collaboration with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR^® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR^® THV is made using a single piece of molded ADAPT^® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT^® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR^® THV System is comprised of the DurAVR^® valve, the ADAPT^® tissue, and the balloon-expandable ComASUR^® Delivery System. The safety and efficacy of the DurAVR^® THV are being evaluated in the PARADIGM Trial (NCT07194265), with the first patients enrolled and implanted with the DurAVR^® THV in Denmark during the fourth quarter of 2025.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements include, but are not limited to, any statements regarding the Offering and the Private Placement, the anticipated use of the net proceeds of the Offering and the Private Placement, and that the underwriters may engage in stabilizing actions or related activities in connection with the Offering. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under “Risk Factors” in the Form S-3 Registration Statement and the preliminary prospectus supplement and accompanying prospectus related to the Offering. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, the Company does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.

For more information:
Investor Relations	Investor Relations (US)
investors@anteristech.com	mchatterjee@bplifescience.com
Debbie Ormsby	Malini Chatterjee, Ph.D.
Anteris Technologies Global Corp.	Blueprint Life Science Group
+61 1300 550 310 | +61 7 3152 3200	+1 917 330 4269

FAQ

How many shares did Anteris (AVR) offer in the January 2026 public offering and at what price?

Anteris offered 34,782,609 shares at $5.75 per share.

What are the expected gross proceeds and closing date for Anteris's (AVR) offering?

The offering is expected to generate approximately $200.0 million in gross proceeds and to close on January 22, 2026.

What is the size and condition of the Medtronic private placement in relation to AVR's offering?

Medtronic may purchase up to $90.0 million of shares at the offering price, subject to buying between 16.0% and 19.99% of post-offering shares; completion of the private placement is contingent on the Offering.

How will Anteris (AVR) use the net proceeds from the public offering?

Proceeds are intended to support the PARADIGM pivotal trial for DurAVR THV, expand manufacturing, fund R&D at v2vmedtech, and for working capital and general corporate purposes.

Does the underwriter have an option to buy more AVR shares after the offering?

Yes; underwriters have a 30-day option to purchase up to an additional 5,217,391 shares at the public offering price, less discounts and commissions.